Tandem Diabetes Care (TNDM) analyst forecast and price target
Analyst forecast
Consensus of 23 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| William Blair | Initiated Coverage | Outperform | — | Aug 21, 2026 |
| RBC Capital | Maintained | Outperform | $26.00 from $30.00 | Aug 7, 2026 |
| Citigroup | Maintained | Neutral | $21.00 from $17.00 | Aug 7, 2026 |
| UBS | Initiated Coverage | Neutral | $18.00 from $22.00 | Jul 28, 2026 |
| Mizuho | Maintained | Neutral | $20.00 from $24.00 | Jul 15, 2026 |
| Deutsche Bank | Initiated Coverage | Buy → Hold | $15.50 | Jun 23, 2026 |
| Wells Fargo | Upgraded | Equal-Weight → Overweight | $27.00 from $21.00 | Jun 1, 2026 |
| Citigroup | Maintained | Neutral | $17.00 from $22.00 | May 28, 2026 |
| B of A Securities | Maintained | Neutral | $25.00 from $35.00 | May 18, 2026 |
| Benchmark | Initiated Coverage | Hold | — | May 12, 2026 |
| Barclays | Maintained | Overweight | $55.00 from $56.00 | May 11, 2026 |
| Truist Securities | Maintained | Buy | $31.00 from $35.00 | May 11, 2026 |
| TD Cowen | Maintained | Buy | $28.00 from $25.00 | Apr 20, 2026 |
| Goldman Sachs | Maintained | Neutral | $25.00 from $28.00 | Apr 9, 2026 |
| Truist Securities | Upgraded | Hold → Buy | $35.00 from $27.00 | Mar 19, 2026 |
| Piper Sandler | Upgraded | Neutral → Overweight | $33.00 from $21.00 | Mar 17, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $25.00 from $23.00 | Mar 2, 2026 |
| Truist Securities | Maintained | Hold | $27.00 from $24.00 | Feb 23, 2026 |
| Lake Street | Upgraded | Hold → Buy | $50.00 | Feb 23, 2026 |
| B of A Securities | Upgraded | Underperform → Neutral | $30.00 from $15.00 | Feb 20, 2026 |
Frequently asked questions
What is the price target for TNDM stock?
The average 12-month analyst price target for Tandem Diabetes Care (TNDM) is $21.25, with a high estimate of $27.00 and a low of $15.50, across 6 analysts.
Is TNDM a buy, sell, or hold?
Analysts covering Tandem Diabetes Care currently average a Buy rating: 12 buy, 11 hold and 0 sell, from 23 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for TNDM?
The average price target of $21.25 implies 3.45% downside from the last price of $22.01.
What is the latest analyst rating on TNDM?
On Aug 21, 2026, William Blair initiated coverage of Tandem Diabetes Care at Outperform.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.